The patient journey: a report of skin cancer care across Europe

Br J Dermatol. 2012 Aug:167 Suppl 2:43-52. doi: 10.1111/j.1365-2133.2012.11086.x.

Abstract

Background: There are poorly documented variations in the journey a skin cancer patient will follow from diagnosis to treatment in the European Union.

Objectives: To investigate the possible difficulties or obstacles that a person with a skin malignancy in the European Union may have to overcome in order to receive adequate medical screening and care for his/her condition. In addition, we wished to explore differences in European health systems, which may lead to health inequalities and health inequities within Europe.

Methods: Ten European countries took part in this investigation (in alphabetical order): Finland, Germany, Greece, Italy, Malta, Poland, Romania, Spain, the Netherlands and the U.K. The individual participants undertook local and national enquiries within their own country and completed a questionnaire.

Results: This exercise has identified important differences in the management of a skin cancer patient, reflecting major disparities in health care between European countries.

Conclusions: Further investigation of health disparities and efforts to address health inequalities should lead to improvements in European health care quality and reduction in morbidity from skin cancer.

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use
  • Costs and Cost Analysis
  • Dermatologic Agents / economics
  • Dermatologic Agents / therapeutic use
  • Dermatology
  • Drug Costs
  • European Union
  • General Practitioners / supply & distribution
  • Healthcare Disparities / economics
  • Healthcare Disparities / statistics & numerical data*
  • Humans
  • Practice Guidelines as Topic
  • Referral and Consultation / statistics & numerical data
  • Skin Neoplasms / diagnosis
  • Skin Neoplasms / economics
  • Skin Neoplasms / therapy*
  • Workforce

Substances

  • Antineoplastic Agents
  • Dermatologic Agents